The study, "Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies,” published in the July 2026 issue of The American Journal of Managed Care® (AJMC®), found that after the FDA approved Wegovy for cardiovascular risk reduction in March 2024 and Medicare Part D expanded coverage accordingly, total Wegovy fills rose 136.4% compared with the pre-policy period, with Medicare Part D fills surging 598.1%. However, fewer than 1% of the estimated 3.6 million eligible beneficiaries had actually filled a prescription by September 2024.
Ad Hoc News cites these AJMC findings directly to illustrate a persistent chasm between eligibility and real-world uptake, using the stark contrast between the dramatic prescription surge and the negligible share of eligible patients actually filling prescriptions to support its argument that Novo Nordisk's recent stock rally is grounded more in market promise than in proven demand.
The AJMC study, “The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness,” published in the June 2026 issue, found that states with higher Medicaid reimbursement rates for psychiatrists had 24% lower overall health care costs and 19% lower psychiatric-specific costs among patients with serious mental illness, along with significantly reduced emergency department and inpatient utilization.
MenaFN's retirement planning piece cites these findings to argue that provider participation rates reflect the broader strength of a community's health care system and that retirees should weigh local psychiatric and specialist access as heavily as housing prices and weather when choosing where to live.
The article, “Falling Vaccine Coverage Threatens a Surge in Preventable Diseases," published on AJMC.com, the website of AJMC, reports that millions of cases of preventable infections are likely to occur over the next 25 years if childhood vaccination rates continue to decline, with measles at risk of returning to endemic levels first. Even current vaccination levels may be insufficient without improved coverage and a stronger public health response.
Impakter's piece cites the AJMC outbreak modeling directly to warn that rising vaccine exemption rates driven by skepticism could make measles endemic in parts of the US again, using it as a scientific anchor for its broader argument that evidence-based policy under a One Health framework is urgently needed to counter the public health damage caused by anti-vaccine leadership at HHS.
